Cost-Effectiveness Analysis of Brentuximab Vedotin in Adults with Relapsed or Refractory Hodgkin’s Lymphoma
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2217
https://www.valueinhealthjournal.com/article/S1098-3015(16)33583-5/fulltext
Title :
Cost-Effectiveness Analysis of Brentuximab Vedotin in Adults with Relapsed or Refractory Hodgkin’s Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33583-5&doi=10.1016/j.jval.2016.09.2217
First page :
A734
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2104